Effect of Tangniaole capsule assisted with metformin in newly diagnosed type 2 diabetes patients with blood glucose, urine glucose and insulin resistance level
10.3969/j.issn.1005-1678.2017.09.026
- VernacularTitle:糖尿乐胶囊辅助二甲双胍对初诊2型糖尿病患者血糖、尿糖及胰岛素抵抗水平的影响
- Author:
Liqin FANG
;
Yinjuan FANG
- Keywords:
Tangniaole capsule;
metformin;
type 2 diabetes mellitus;
insulin resistance;
blood glucose and urine glucose
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(9):70-71
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the Tangniaole capsule assisted metformin on newly diagnosed type 2 diabetic patients influence blood glucose, urine glucose and insulin resistance level. Methods 80 patients with newly diagnosed type 2 diabetes mellitus were selected from January 2015 to October 2016 in our hospital. They were randomly divided into the control group and the experimental group, with 40 patients in each group. The control group was treated with metformin, and the experimental group was treated with metformin. Comparative analysis of blood and urine glucose and insulin in patients of the experimental group and the control level of resistance. Results After the corresponding treatment, the insulin resistance index in the experimental group was (2.31±0.51), and the insulin resistance index in the control group was (2.98±0.71). The insulin resistance index of the control group was significantly higher than that of the experimental group, with statistical difference (P<0.05). The fasting blood glucose level (7.31±1.02) nmol / Lin the experimental group was significantly lower than that in the control group (7.90±0.82)nmol / L, with statistical difference (P<0.05). Urine glucose levels of patients in the experimental group was significantly better than the control group, with statistical difference (P<0.05). Conclusion The application of Tangniaole capsule assisted with metformin in newly diagnosed type 2 diabetic patients in can largely reduce blood glucose and urine glucose and insulin resistance level, with further clinical promotion and application significance.
